Literature DB >> 14580081

Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression.

N Michael1, A Erfurth, P Ohrmann, V Arolt, W Heindel, B Pfleiderer.   

Abstract

BACKGROUND: The dorsolateral prefrontal cortex (DLPFC) is involved in the pathophysiology of major depression. In particular, metabolic (functional hypometabolism) and structural alterations have been described. In this study metabolic changes within the DLPFC of severely depressed patients before and after electroconvulsive therapy (ECT) were evaluated by proton STEAM spectroscopy (1H-MRS).
METHOD: Twelve severely depressed patients with a diagnosis of major depressive episode, unipolar with melancholic features (DSM-IV), were enrolled, and the left dorsolateral prefrontal cortex (DLPFC) was investigated before and after unilateral ECT by 1H-MRS. Three of the four non-responding patients were remeasured a third time after a combined ECT/antidepressant pharmacotherapy. The results were compared with 12 age- and gender-matched controls.
RESULTS: In depressed patients reduced glutamate/glutamine (Glx) levels were measured pre-ECT; Glx concentrations correlated negatively with severity of depression. After successful treatment, Glx increased significantly and levels no longer differed from those of age-matched controls.
CONCLUSIONS: Our results indicate that major depressive disorder is accompanied by state-dependent metabolic alterations, especially in glutamate/glutamine metabolism, which can be reversed by successful ECT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580081     DOI: 10.1017/s0033291703007931

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  58 in total

Review 1.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

Review 2.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 3.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

4.  Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy.

Authors:  Marc J Dubin; Xiangling Mao; Samprit Banerjee; Zachary Goodman; Kyle A B Lapidus; Guoxin Kang; Conor Liston; Dikoma C Shungu
Journal:  J Psychiatry Neurosci       Date:  2016-04       Impact factor: 6.186

Review 5.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

6.  Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats.

Authors:  Patricia J Allen; Kristen E D'Anci; Robin B Kanarek; Perry F Renshaw
Journal:  Pharmacol Biochem Behav       Date:  2012-03-10       Impact factor: 3.533

7.  Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice.

Authors:  Younghyurk Lee; Hyeonwi Son; Gyeongwha Kim; Sujeong Kim; Dong Hoon Lee; Gu Seob Roh; Sang Soo Kang; Gyeong Jae Cho; Wan Sung Choi; Hyun Joon Kim
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

8.  Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression.

Authors:  Talaignair N Venkatraman; Ranga R Krishnan; David C Steffens; Allen W Song; Warren D Taylor
Journal:  Psychiatry Res       Date:  2009-04-30       Impact factor: 3.222

9.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression.

Authors:  Anteneh M Feyissa; Agata Chandran; Craig A Stockmeier; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-10-25       Impact factor: 5.067

10.  Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers.

Authors:  M J Taylor; R Norbury; S Murphy; S Rudebeck; P Jezzard; P J Cowen
Journal:  J Psychopharmacol       Date:  2009-05-07       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.